• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

下调 LEMD1-AS1 及其对上皮性卵巢癌的诊断、预后和免疫浸润的影响。

Downregulation of LEMD1-AS1 and Its Influences on the Diagnosis, Prognosis, and Immune Infiltrates of Epithelial Ovarian Cancer.

机构信息

Department of Obstetrics and Gynaecology, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi, 445000 Hubei Province, China.

Clinical Laboratory Center, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, No. 158 Wuyang Avenue, Enshi City, 445000 Hubei Province, China.

出版信息

Dis Markers. 2022 Aug 3;2022:6408879. doi: 10.1155/2022/6408879. eCollection 2022.

DOI:10.1155/2022/6408879
PMID:35968498
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9365578/
Abstract

Previous studies have confirmed long noncoding RNA LEMD1-AS1 (LEMD1-AS1) as a functional factor in several tumors. The present work is aimed at exploring the prognostic and diagnostic values of LEMD1-AS1 in patients with epithelial ovarian cancer (EOC). We examined the expressions of LEMD1-AS1 in pan-cancer from TCGA microarray datasets and GTEx Project. The expressions of LEMD1-AS1 were detected by qRT-PCR in EOC specimens and normal ovarian specimens from 30 EOC patients. The test was applied to compare the clinicopathological characteristics of different groups. ROC curves were established to determine the diagnostic values of LEMD1-AS1 in screening EOC tissues. The association of LEMD1-AS1 expression with clinical outcome was determined by the Kaplan-Meier methods and COX assays. A decreased expression of LEMD1-AS1 was observed in EOC tissues compared to matched normal specimens ( < 0.01). Low LEMD1-AS1 expression could be used to distinguish EOC from adjacent normal specimens. A clinical study revealed that patients with low LEMD1-AS1 expression have a shorter overall survival ( = 0.035) and progress-free interval ( = 0.041) than those with high LEMD1-AS1 expression. The Spearman correlation test revealed that LEMD1-AS1 expressions were negatively associated with the expressions of neutrophil and myeloid dendritic cell. Overall, our finding suggested that LEMD1-AS1 may have potential roles as a potential biomarker and/or a therapeutic target in EOC.

摘要

先前的研究已经证实，长链非编码 RNA LEMD1-AS1（LEMD1-AS1）是几种肿瘤中的功能因子。本研究旨在探讨 LEMD1-AS1 在卵巢上皮癌（EOC）患者中的预后和诊断价值。我们从 TCGA 微阵列数据集和 GTEx 项目中检查了 LEMD1-AS1 在泛癌中的表达。通过 qRT-PCR 在 30 例 EOC 患者的 EOC 标本和正常卵巢标本中检测 LEMD1-AS1 的表达。 检验用于比较不同组的临床病理特征。ROC 曲线用于确定 LEMD1-AS1 在筛选 EOC 组织中的诊断价值。Kaplan-Meier 方法和 COX 检验确定 LEMD1-AS1 表达与临床结局的相关性。与匹配的正常标本相比，EOC 组织中观察到 LEMD1-AS1 的表达降低（ < 0.01）。低表达 LEMD1-AS1 可用于区分 EOC 与相邻正常标本。临床研究表明，低表达 LEMD1-AS1 的患者总生存期（ = 0.035）和无进展间隔（ = 0.041）较短，而高表达 LEMD1-AS1 的患者总生存期（ = 0.035）和无进展间隔（ = 0.041）较短。Spearman 相关检验显示 LEMD1-AS1 的表达与中性粒细胞和髓样树突状细胞的表达呈负相关。总的来说，我们的研究结果表明，LEMD1-AS1 可能在 EOC 中作为一种潜在的生物标志物和/或治疗靶点发挥作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bda9/9365578/ef4b725c267f/DM2022-6408879.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bda9/9365578/f5f7ce086476/DM2022-6408879.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bda9/9365578/d62ffa5e1a07/DM2022-6408879.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bda9/9365578/eefd18c01711/DM2022-6408879.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bda9/9365578/ef4b725c267f/DM2022-6408879.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bda9/9365578/f5f7ce086476/DM2022-6408879.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bda9/9365578/d62ffa5e1a07/DM2022-6408879.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bda9/9365578/eefd18c01711/DM2022-6408879.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bda9/9365578/ef4b725c267f/DM2022-6408879.004.jpg

相似文献

1
Downregulation of LEMD1-AS1 and Its Influences on the Diagnosis, Prognosis, and Immune Infiltrates of Epithelial Ovarian Cancer.下调 LEMD1-AS1 及其对上皮性卵巢癌的诊断、预后和免疫浸润的影响。
Dis Markers. 2022 Aug 3;2022:6408879. doi: 10.1155/2022/6408879. eCollection 2022.
2
A prognostic model based on immune-related long noncoding RNAs for patients with epithelial ovarian cancer.基于免疫相关长非编码 RNA 的上皮性卵巢癌预后模型。
J Ovarian Res. 2022 Jan 15;15(1):8. doi: 10.1186/s13048-021-00930-w.
3
Long Noncoding RNA LINC01554 as a Novel Biomarker for Diagnosis and Prognosis Prediction of Epithelial Ovarian Cancer.长链非编码RNA LINC01554作为上皮性卵巢癌诊断和预后预测的新型生物标志物
Dis Markers. 2021 Aug 10;2021:1244612. doi: 10.1155/2021/1244612. eCollection 2021.
4
Increased expression of long noncoding RNA HMMR-AS1 in epithelial ovarian cancer: an independent prognostic factor.长链非编码 RNA HMMR-AS1 在卵巢上皮性癌中的表达增加：一个独立的预后因素。
Eur Rev Med Pharmacol Sci. 2018 Dec;22(23):8145-8150. doi: 10.26355/eurrev_201812_16506.
5
KCNMA1-AS1 attenuates apoptosis of epithelial ovarian cancer cells and serves as a risk factor for poor prognosis of epithelial ovarian cancer.KCNMA1反义链1可减轻上皮性卵巢癌细胞的凋亡，并作为上皮性卵巢癌预后不良的一个危险因素。
Eur Rev Med Pharmacol Sci. 2019 Jun;23(11):4629-4641. doi: 10.26355/eurrev_201906_18041.
6
Overexpression of long noncoding RNA PTPRG-AS1 is associated with poor prognosis in epithelial ovarian cancer.长链非编码RNA PTPRG-AS1的过表达与上皮性卵巢癌的不良预后相关。
Rev Assoc Med Bras (1992). 2020 Jul;66(7):948-953. doi: 10.1590/1806-9282.66.7.948. Epub 2020 Aug 24.
7
Down-regulation of long noncoding RNA DLX6-AS1 defines good prognosis and inhibits proliferation and metastasis in human epithelial ovarian cancer cells via Notch signaling pathway.长链非编码 RNA DLX6-AS1 的下调定义了良好的预后，并通过 Notch 信号通路抑制人卵巢上皮癌细胞的增殖和转移。
Eur Rev Med Pharmacol Sci. 2019 Apr;23(8):3243-3252. doi: 10.26355/eurrev_201904_17684.
8
Downregulation of lncRNA ASMTL-AS1 in Epithelial Ovarian Cancer Correlates with Worse Prognosis and Cancer Progression.lncRNA ASMTL-AS1 在卵巢上皮性癌中的下调与更差的预后和癌症进展相关。
Horm Metab Res. 2022 Jul;54(7):481-488. doi: 10.1055/a-1872-0546. Epub 2022 Jul 14.
9
An Integrative Analysis Revealing ZFHX4-AS1 as a Novel Prognostic Biomarker Correlated with Immune Infiltrates in Ovarian Cancer.一项整合分析揭示 ZFHX4-AS1 作为一种新型的与卵巢癌免疫浸润相关的预后生物标志物。
J Immunol Res. 2022 Jun 26;2022:9912732. doi: 10.1155/2022/9912732. eCollection 2022.
10
Serum lncRNA LOXL1-AS1 is a diagnostic and prognostic marker for epithelial ovarian cancer.血清 lncRNA LOXL1-AS1 是上皮性卵巢癌的诊断和预后标志物。
J Gene Med. 2020 Oct;22(10):e3233. doi: 10.1002/jgm.3233. Epub 2020 Jun 13.

引用本文的文献

1
Latest Update on lncRNA in Epithelial Ovarian Cancer-A Scoping Review.上皮性卵巢癌中长链非编码RNA的最新进展——一项综述。
Cells. 2025 Apr 7;14(7):555. doi: 10.3390/cells14070555.
2
The roles of long non-coding RNAs in ovarian cancer: from functions to therapeutic implications.长链非编码RNA在卵巢癌中的作用：从功能到治疗意义
Front Oncol. 2024 Apr 25;14:1332528. doi: 10.3389/fonc.2024.1332528. eCollection 2024.

本文引用的文献

1
Noncoding RNA therapeutics - challenges and potential solutions.非编码 RNA 治疗学——挑战与潜在解决方案。
Nat Rev Drug Discov. 2021 Aug;20(8):629-651. doi: 10.1038/s41573-021-00219-z. Epub 2021 Jun 18.
2
Cancer Statistics, 2021.癌症统计数据，2021.
CA Cancer J Clin. 2021 Jan;71(1):7-33. doi: 10.3322/caac.21654. Epub 2021 Jan 12.
3
Unraveling tumor-immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy.解析晚期卵巢癌肿瘤免疫异质性揭示化疗的免疫原性效应。
Nat Genet. 2020 Jun;52(6):582-593. doi: 10.1038/s41588-020-0630-5. Epub 2020 Jun 1.
4
mutation in high grade epithelial ovarian cancers.高级别上皮性卵巢癌中的突变
Gynecol Oncol Rep. 2019 Aug 13;29:102-105. doi: 10.1016/j.gore.2019.07.007. eCollection 2019 Aug.
5
Management of rare epithelial ovarian cancers.罕见上皮性卵巢癌的管理
Clin Adv Hematol Oncol. 2019 Aug;17(8):444-446.
6
Pharmaceutical Management of Ovarian Cancer: Current Status.卵巢癌的药物治疗管理：现状。
Drugs. 2019 Jul;79(11):1231-1239. doi: 10.1007/s40265-019-01158-1.
7
Long noncoding RNA NORAD is upregulated in epithelial ovarian cancer and its downregulation suppressed cancer cell functions by competing with miR-155-5p.长链非编码 RNA NORAD 在卵巢上皮性癌中上调，其下调通过与 miR-155-5p 竞争抑制癌细胞功能。
Cancer Med. 2019 Aug;8(10):4782-4791. doi: 10.1002/cam4.2350. Epub 2019 Jun 28.
8
Epithelial ovarian cancer: Evolution of management in the era of precision medicine.上皮性卵巢癌：精准医学时代的治疗进展。
CA Cancer J Clin. 2019 Jul;69(4):280-304. doi: 10.3322/caac.21559. Epub 2019 May 17.
9
CREB1 induced lncRNA HAS2-AS1 promotes epithelial ovarian cancer proliferation and invasion via the miR-466/RUNX2 axis.CREB1 诱导的长链非编码 RNA HAS2-AS1 通过 miR-466/RUNX2 轴促进卵巢上皮性癌细胞的增殖和侵袭。
Biomed Pharmacother. 2019 Jul;115:108891. doi: 10.1016/j.biopha.2019.108891. Epub 2019 May 10.
10
Pathologic response to neoadjuvant chemotherapy in advanced ovarian cancer: utility of a scoring system to predict outcomes.晚期卵巢癌新辅助化疗的病理反应：预测结局的评分系统的效用。
Int J Gynecol Cancer. 2019 Jul;29(6):1064-1071. doi: 10.1136/ijgc-2019-000232. Epub 2019 May 5.